Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceruletide is a decapeptide originally isolated from the skin of the Australian green tree frog (Ranoidea caerulea). It is structurally and functionally similar to the gastrointestinal hormone cholecystokinin. Ceruletide acts as an agonist at cholecystokinin receptor (primarily CCK1 and CCK2), stimulating gastric acid secretion, biliary and pancreatic secretions, and smooth muscle contraction in the gastrointestinal tract. Clinically, it has been used as a diagnostic agent for evaluating pancreatic exocrine function and gallbladder motility (e.g., in x-ray examination of the gallbladder or small bowel) and therapeutically for conditions such as paralytic ileus. Ceruletide has also been investigated for its analgesic properties in cancer pain and other pain syndromes. In research settings, it is commonly used to induce experimental pancreatitis in animal models[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceruletide.